Table 1.
Most significant pathways and networks identified by IPA of genes showing significant (p < 0.001) promoter hypermethylation (A) and hypomethylation (B) of the schizophrenia affected vs. healthy monozygotic twins in twin pair 1
| A) | ||
|---|---|---|
| Canonical Pathways | P-value | Ratioa |
| HIPPO signaling | 3.93E-03 | 4/85 (0.047) |
| MAPK Signaling | 4.27E-03 | 4/87 (0.046) |
| Molecular and Cellular Functions | ||
| Cell Cycle, DNA Replication, Recombination | 1.69E-04–1.51E-02 | 6 |
| Cellular development, growth and proliferation | 1.16E-03–4.45E-02 | 24 |
| Cell Death and Survival | 1.67E-03–4.54E-02 | 22 |
| Diseases and Disorders | ||
| Developmental disorder | 3.56E-03–4.72E-02 | 16 |
| Hereditary disorder | 3.56E-03–2.99E-02 | 22 |
| Organismal injury and abnormalities | 3.56E-03–4.91E-02 | 45 |
| Most Significant Networks | #of molecules | |
| Cellular Growth, Proliferation, Cellular movement & development | 131 | |
| Cell Death and Survival, Cellular movement | 69 | |
| B) | ||
| Canonical Pathways | P-value | Ratioa |
| Dopamine-DARPP32 feedback in cAMP signaling | 7.43E-03 | 6/157 (0.038) |
| Calcium Signalling | 1.08E-02 | 6/170 (0.035) |
| Ephrin Receptor Signalling | 1.13E-02 | 6/172 (0.035) |
| Molecular and Cellular Functions | ||
| Gene expression | 3.75E-04–4.97E-02 | 37 |
| Cellular Assembly and Organization | 1.15E-03–4.61E-02 | 22 |
| Small Molecule Biochemistry | 3.39E-03–4.51E-02 | 16 |
| Lipid Metabolism | 3.39E-03–3.69E-02 | 6 |
| Diseases and disorders | # of molecules | |
| Metabolic disease | 3.38E-04–4.28E-02 | 17 |
| Endocrine system disorders | 1.95E-04–4.42E-02 | 21 |
| Nervous system development and function | 1.71E-03–4.28E-02 | 3 |
| Most Significant Networks | ||
| Cell-mediated Immune Response, Cellular Movement | 60 | |
| Cell Cycle, Cellular Development | 56 | |
aThe number of molecules that reach the threshold of significant methylation difference between twins
(Peak score > =3.1)